PRAME in Oral Precancer and Cancer

High morbidity and mortality in oral cancers, necessitates early diagnosis and effective management. Despite ease in morphological accessibility, diagnosis occurs mostly in advanced stages attributed to lack of effective and cheap screening tools and suitable biomarker, which can diagnose oral cancer effectively and can predict the progression of Oral precancer to Cancer accurately. PRAME (Preferentially Expressed Antigen of Melanoma) is one such biomarker, which is a dominant repressor of Vitamin A. Vitamin A or its chief component Retinoic Acid (RA) is extensively used these days for chemo-prevention owing to its role in cell growth and differentiation. RA emerged as a cheap and acceptable chemopreventive agent. But its efficiency is still debatable owing to mixed outcomes in various cancers. Inconsistency in efficient results led to study of various molecules like PRAME, which is involved in RA metabolic pathway thereby modulating the outcome and efficacy of RA chemoprevention. This book aims to acquaint its readers with the basic role and potential of PRAME in predicting the responsiveness of RA in cancer therapeutics and directs for future therapy targeting PRAME.

Autorentext

Dr Ruby is an Oral Pathologist and experienced researcher with several publications in indexed journals. She has been awarded several times for her research work. Her keys areas of interest include internet of things, 3D Bioprinting and Bioengineering.